Trials / Unknown
UnknownNCT04650633
SHR-1701 in Patients With Recurrent/Metastatic Scchn
A Phase II,Open-label Trial to Investigate the Efficacy and Safety of SHR-1701 in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial. |
Timeline
- Start date
- 2021-05-07
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
- First posted
- 2020-12-02
- Last updated
- 2021-10-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04650633. Inclusion in this directory is not an endorsement.